Skip to content

A study to know the effect of Siddha basti and Siddha basti with valuka sweda in Amavata(Rheumatoid arthritis)

An Open Label Double Arm Comparative Clinical Study On The Effect of Siddha Basti and Siddha Basti with Valuka Sweda in Amavata(Rheumatoid arthritis) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072551
Enrollment
30
Registered
2024-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

None listed

Sponsors

Dr Pranathi G Kashyap
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Amavata with features of Rheumatoid arthritis as specified in 2010 ACR-EULAR classification criteria. 2.Irrespective of serological negativity and positivity are included for the study. 3.Patients fit for Basti karma. 4.Patient of either gender with the age group 30 to 60 years. 5.Recent onset and less than or equal to 5 years of chronicity. 6.Considering disease activity and functional impairment STAGE-1, STAGE-2 7.Patients voluntarily willing to participate in the study and ready to sign consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with known case of uncontrolled hypertension and diabetes mellitus. 2.Patients with cardiac manifestations. 3.Patients diagnosed with other degenerative and inflammatory joint diseases, history of knee implants and total knee replacement surgeries. 4.Patients with the signs and symptoms of Pravruddha amavata21 with joint deformities STAGE-3, STAGE-4. 5.Active tuberculosis, Ulcerative colitis, Irritable bowel syndrome or other sever systemic and endocrine disorders. 6.Patients of Ano-Rectal disorders. 7.Pregnancy and lactating women. 8.Patients with cerebrovascular accident. 9.Patients who are receiving chemotherapy and radiotherapy.

Design outcomes

Secondary

MeasureTime frame
• Significant improvement in DAS 28Score • Improved Quality of life related to joints. Timepoint: 0th day(before treatment), 9th day(after treatment) and 24th day(after treatment)

Primary

MeasureTime frame
•Significant improvement in Sandhi shola (joint pain) measured using VAS(Visual analog scale) •Significant improvement in Sandhi sthabdhata(morning stiffness) using Gradings •Significant improvement in Sandhi shotha(joint swelling) using gradings •Significant improvement in Tenderness using gradings Timepoint: 0th day(before treatment),9th day(after treatment) and 24th day(after treatment)

Countries

India

Contacts

Public ContactDr Basavaraj G Saraganachari

Shri Dharmasthala Manjunatheshwara Institute of Ayurveda and Hospital

drbasugs@gmail.com9448008022

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026